Date: November 3, 2021
Time: 7:00am (PDT), 10:00am (EDT)
The reconstitution of a fully functional human immune system in mouse after engraftment of purified hCD34+ hematopoietic cells provide a unique opportunity to assess the efficacy of new oncology drug candidates acting on human immune cells (e.g. T cells, myeloid cells, NK cells) and on the tumor itself. This webinar reports on the different CDX/PDX successfully engrafted in the hu-mice models and their characterization regarding their TILs content. Immune Check Point inhibitors, such as anti-PD1 reduced tumor growth in hu-mice and can be used in combination with newly developed drugs demonstrating the usefulness of this model in onco-immunology. Hu-mice have been further optimized to boost the differentiation of myeloid and NK cells, allowing scientists to efficiently test new antibodies or small molecules targeting those immune cell populations, like vaccine, ADCC, macrophage balance. TransCure bioServices is the only preclinical CRO providing immuno-oncology, inflammatory, infectious disease models in hu-mice.
- Discuss the main characteristics of a predictive CD34+ human immune system mouse model
- Describe how to select the best cancer cell lines based on TILs profiling
- Discuss IO case studies: ICP inhibitor, ADCC, CAR-T, vaccination
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.